+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ophthalmoplegia Drug"

Ophthalmoplegia - Pipeline Insight, 2024 - Product Thumbnail Image

Ophthalmoplegia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Ophthalmoplegia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Ophthalmoplegia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Ophthalmoplegia Market Report and Forecast 2024-2032 - Product Thumbnail Image

Ophthalmoplegia Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Ophthalmoplegia is a condition that affects the muscles of the eye, causing them to become weak or paralyzed. It can be caused by a variety of conditions, including stroke, multiple sclerosis, and brain tumors. Treatment for ophthalmoplegia typically involves medications that help to improve the strength and coordination of the eye muscles. These medications are known as optical disorders drugs. Optical disorders drugs are used to treat a variety of conditions, including ophthalmoplegia. These drugs work by improving the strength and coordination of the eye muscles, allowing them to move more freely. They can also help to reduce inflammation and pain associated with the condition. Common optical disorders drugs include corticosteroids, anticholinergics, and botulinum toxin. The ophthalmoplegia drug market is a rapidly growing sector of the pharmaceutical industry. It is driven by the increasing prevalence of ophthalmoplegia and other optical disorders, as well as advances in medical technology. Companies in this market include Allergan, Novartis, and Pfizer. Show Less Read more